Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Jul

2010

Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Apr

2010

Genticel, S.A.: Series C $17.7M

Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - HPV, X - Oncology, X - THx, X - Vaccines

Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.

Feb

2010

Regado Biosciences, Inc.: Series D $40M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

PDC Biotech, GmbH: Series A $5.5M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Dysmenorrhea

PDC Biotech (Austria) a preclinical-stage biopharmaceutical company focused upon women’s health preterm labor and primary dysmenorrhea, closed a $5.5M Series A financing. Participants include MIG Verwaltungs and Edmond de Rothschild Investment Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Probiodrug, AG: Series B $54M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Alzheimer's, X - Inflammation

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...